LifeCycle sells North American royalties for Fenoglide

08/21/2008 | Reuters

LifeCycle Pharma, a Danish biotech company, has sold the North American royalty stream from its drug Fenoglide to Cowen Healthcare Royalty Partners in a deal worth as much as $105 million. Fenoglide, a cholesterol-lowering treatment, entered the U.S. market this year through Sciele Pharma.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA